miR-21通过调节NF-κB信号途径对感染性早产发病机制的影响

基本信息
批准号:81560254
项目类别:地区科学基金项目
资助金额:38.00
负责人:段丽君
学科分类:
依托单位:甘肃省人民医院
批准年份:2015
结题年份:2019
起止时间:2016-01-01 - 2019-12-31
项目状态: 已结题
项目参与者:王金羊,单龙,刘凤磊,杨雪萍,王蓉蓉,杜盟盟
关键词:
感染性早产核因子κB绒毛膜滋养层细胞microRNA21
结项摘要

Infectious preterm birth (IPTB) is the main factors resulted in the higher morbidity and mortality of perinatal infant, which its mechanism has not been fully elucidated. MiR-21 was the key component of the NF-κB regulation network, which played an important role in NF-κB-mediated inflammatory pathway. Our preliminary experiments showed that miR-21 overexpression downregulated NF-κB protein, and inhibition of miR-21 upregulated NF-κB protein. Hereby, we speculated that miR-21 may be involved in onset process of IPTB by adjusting NF-κB pathway. In this study, chorioamnionitis was as a center-link of IPTB, miR-21 and NF-κB was as the key breakthrough point in the inflammation regulation network, glucocorticoid hormone drugs-dexamethasone (DXM) was for the intervention measures. We further explore whether miR-21 was involved in IPTB by NF-κB signaling pathways, and influence of DXM on miR-21expression. This study will help to formulate the strategies of treatment and prevention for IPTB, and provide new direction for research and development of new miRNAs-target drug.

感染性早产(Infectious preterm birth,IPTB)是导致围生儿发病率和死亡率升高的最主要因素,其机制尚未完全阐明。miR-21在NF-κB 介导的炎症通路中发挥着重要调节功能,是NF-κB调控网络中的关键成分。我们前期实验发现:miR-21过表达下调NF-κB蛋白表达,而抑制miR -21则上调NF-κB蛋白表达;故推测miR-21可能通过调节NF-κB通路参与IPTB发病过程。故本课题针对IPTB发病的中心环节——绒毛膜羊膜炎,以炎症调控网络中的关键成分miR-21和NF-κB为切入点,以糖皮质激素类药物地塞米松(dexamethasone,DXM)为干预措施,从整体、细胞、分子水平三个层次探讨miR-21通过NF-κB信号途径在IPTB中的作用以及DXM对miR-21的影响,将有助于制定IPTB的治疗和预防策略,研发新型药物的靶标提供新的方向。

项目摘要

感染性早产(IPTB)是导致围生儿发病率和死亡率升高的最主要因素。本课题采用LPS诱导感染性早产模型和滋养层细胞模型,针对IPTB发病的中心环节——绒毛膜羊膜炎,以炎症调控网络中的关键成分miR-21和NF-κB为切入点,以经典的糖皮质激素类药物DXM为干预措施。采用RT-PCR, western-bloting,细胞转染,激光共聚焦等技术通过观察胎盘绒毛膜组织和滋养层细胞miR-21的表达及DXM干预作用。结果阐明:(1)miR-21通过调节NF-κB信号通路参与IPTB的发病机制;(2)DXM能够剂量依赖性的促进miR-21的表达,miR-21有可能是DXM治疗IPTB新的作用靶点;(3)miR-21 mimics替代治疗可改善绒毛膜羊膜炎,该研究有助于研发以miR-21为靶标治疗IPTB的新药提供方向。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

DeoR家族转录因子PsrB调控黏质沙雷氏菌合成灵菌红素

DeoR家族转录因子PsrB调控黏质沙雷氏菌合成灵菌红素

DOI:10.3969/j.issn.1673-1689.2021.10.004
发表时间:2021
2

内点最大化与冗余点控制的小型无人机遥感图像配准

内点最大化与冗余点控制的小型无人机遥感图像配准

DOI:10.11834/jrs.20209060
发表时间:2020
3

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

DOI:10.3389/fcell.2021.735374
发表时间:2021
4

视网膜母细胞瘤的治疗研究进展

视网膜母细胞瘤的治疗研究进展

DOI:
发表时间:2018
5

Bousangine A, a novel C-17-nor aspidosperma-type monoterpenoid indole alkaloid from Bousigonia angustifolia

Bousangine A, a novel C-17-nor aspidosperma-type monoterpenoid indole alkaloid from Bousigonia angustifolia

DOI:10.1016/j.fitote.2020.104491
发表时间:2020

段丽君的其他基金

相似国自然基金

1

HSPA12B对感染性休克内皮功能不全的保护作用及机制研究:对MEK/ERK/NF-κB炎症信号的负调节

批准号:81301616
批准年份:2013
负责人:吴军
学科分类:H1601
资助金额:23.00
项目类别:青年科学基金项目
2

瑞士乳杆菌通过ROS-Hsp72途径抑制人IECs NF-κB信号通路的免疫调节作用机制

批准号:31501496
批准年份:2015
负责人:林秋叶
学科分类:C2004
资助金额:20.00
项目类别:青年科学基金项目
3

清热解毒方对2型糖尿病炎症因子及NF-κB/IκB信号途径的调节作用

批准号:30772799
批准年份:2007
负责人:冯建华
学科分类:H3108
资助金额:26.00
项目类别:面上项目
4

MCPIP1通过NF-κB途径对结直肠癌发生发展的影响及其分子机制

批准号:81702312
批准年份:2017
负责人:叶文
学科分类:H1813
资助金额:21.00
项目类别:青年科学基金项目